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Abstract
Introduction: This paper evaluates tumour control and toxicity especially in relation to swallowing dysfunction in
those patients with locally advanced oropharyngeal squamous cell carcinoma who have undergone either primary
chemo-radiation or post-operative parotid sparing IMRT. The TOM scoring system was used to assess dysphagia.
Methods: All patients with locally advanced (stage 3/4) squamous cell oropharyngeal cancer and who required
either primary or post-operative RT were identified. Toxicity was recorded prospectively. The TOM score (0-5 where
5 indicates that the patient is able to eat a normal diet and 0-2 varying degrees of enteral feeding dependency),
weights and trismus was recorded immediately prior to and following radiotherapy.
Results: 24 patients were identified between 1/2003 and 11/2007. Median weight loss during radiotherapy was 9
kg. All but one patient had a gastrostomy (RIG) tube inserted prophylactically. With a mean follow-up of 37.1
months, 62.5% of pts had a TOM score of 5, 12.5% scored 3, 8% scored and 17% scored 0-2. For those patients
whose swallowing function did recover, it took on average 8.7 months. 15% patients experienced trismus
secondary to radiotherapy. 2 year overall survival was 92% and disease specific survival 96%.
Conclusion: Excellent disease control with intensified schedules of radiotherapy with IMRT has been achieved in
this patient population. Intermediate toxicity is significant but with longer follow-up, dysphagia continues to
improve with 75% of patients not requiring any form of enteral or oral supplementation.
Introduction
Squamous cell carcinoma accounts for about 90% of
new head and neck cancers. There are on average 8000
new cases per year and 3000 deaths in England and
Wales alone (Cancer Research UK). Risk factors for the
development of squamous cell carcinoma of the head
and neck (SCCHN), which is the commonest histologi-
cal variant, include smoking, alcohol and previous radio-
therapy in that locality. Human papilloma virus (HPV)
is an independent risk factor for oropharyngeal carci-
noma, in particular HPV-16 subtype and seropositivity
for the oncoproteins E6 and E7 [1].
The treatment of oropharyngeal carcinoma consists
primarily of surgery, radiotherapy, chemotherapy or a
combination. There is no single therapeutic regimen
that gives a clear-cut superior survival advantage over
another. Treatment choice will be dependent on a num-
ber of patient- and treatment-related factors.
Depending on the subsite, early tumours of the oro-
pharynx may be considered for surgery or irradiation
whereas more locally advanced tumours require a
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radiotherapy, or chemoradiotherapy with salvage surgery
[2]. However, surgery for locally advanced tumours may
result in significant morbidity.
Radiotherapy for both early and advanced base of ton-
gue tumours provides similar local control to surgery
with less long term morbidity therefore is preferable to
surgery [3]. Similarly, radiotherapy alone (or combined
with a neck dissection) for tonsillar carcinoma provides
cure rates as good as surgery with a lower risk of com-
plications [4].
Concurrent chemo-radiation rather than radiotherapy
alone has been shown to significantly reduce the local
recurrence rates and has an absolute benefit of 6.5% at
5 years in particular for patients with locally advanced
disease [5]. This, however, increases toxicity so is only
undertaken in patients with a good performance status.
In addition the impact on functional morbidity has yet
to be fully evaluated. If surgery is undertaken as the pri-
mary treatment, then post-operative radiotherapy may
b eo f f e r e da st h i si m p r o v e so u t c o m ei nn o d ep o s i t i v e
disease [6] or to high risk patients, post-operative che-
moradiotherapy as this has been shown to improve sur-
vival further [7,8].
As non-surgical treatment has intensified in order to
improve tumour control, and surgical techniques for
resection and reconstruction have extended the surgical
options, there is a clear need to consider the quality of
life impact of these intensive often multi-modality sche-
dules. The Liverpool group have been evaluating quality
of life using the University of Washington Quality of
Life questionnaire. They have recently published their
work that augments patients’ understanding of their
treatment but it is based very much on the classical sur-
gery and post-operative radiotherapy scenario [9].
Internationally, work is underway to develop readily
usable core sets of questions based on the International
Classification of Functioning, Disability and Health [10].
The Therapy Outcome Measure (TOM) scoring system
uses these principles. Originally conceived by Enderby
[11] it has been developed further particularly in Austra-
lia as a simple and reproducible way to assess the degree
of dysphagia experienced by patients before, during and
after treatment [12]. When considering outcome mea-
sures to use, Skeat and Perry stress the importance of
the measure being practical to apply and that it presents
an accurate picture of change [13].
This paper therefore evaluates tumour control and
intermediate/late toxicity especially in relation to swal-
lowing dysfunction in those patients with locally
advanced oropharyngeal squamous cell carcinoma who
have undergone either primary chemo-radiation or post-
operative radiotherapy with or without concurrent che-
motherapy. For the purposes of the study we used the
TOM scoring system and specifically, the ‘disability’
descriptor that provided the best fit as a marker of
outcome.
Methods
All patients who were identified with locally advanced
(stage 3/4) squamous cell oropharyngeal cancer irrespec-
tive of tumour type and who required radical radiother-
apy were to be included in the series as long as they
were treated with inverse-planned IMRT either as defi-
nitive or adjunctive therapy.
Initial patients were planned with the Varian Cadplan™
treatment planning system (TPS) (Varian Medical Sys-
tems, Palo Alto, CA), later patients with the Varian
Eclipse TPS ™ both with the Helios™ inverse planning
module.
All patients were treated as standard with contralateral
parotid gland sparing (intended mean dose 26Gy) [14].
A seven field equi-spaced co-planar field arrangement
was used doses in all cases.
Doses were specified to the mean of the PTV. Three
dose levels were specified as appropriate. Dose level ONE:
65Gy/30#/6 weeks to the primary and involved nodes as
definitive RT or post-operatively when margins were
grossly involved or there was extra-capsular extension of
nodes. Dose level TWO: 60/30#/6 weeks to areas consid-
ered at ‘high-risk’ in the definitive setting (e.g. level 3
nodes when level 2 nodes were positive) or the ‘surgical
bed’ in post-operative cases. Dose level THREE: 54Gy/
30#/6 weeks to the remainder of the neck for prophylactic
irradiation (definitive or post-operative). The exception to
this approach was in the post-operative setting where a
few patients received an accelerated schedule i.e. 54Gy/
34#/2.5 weeks as in the MRC Chartwel protocol [15].
Chemotherapy when used was delivered using a
weekly schedule of 35 mg/m
2 for up to 6 cycles. The
criteria for concurrent post-operative chemoradiother-
apy was as per the EORTC study [8]. If the criteria
relating to ‘tumour factors’ were met for concurrent
chemotherapy but there was concern over the patients’
level of fitness/suitability, cetuximab was considered as
an alternative.
Toxicity was recorded prospectively using the RTOG
scoring systems (for both acute and late effects). The
Therapy Outcome Measure (TOM) score was recorded
immediately prior to and following radiotherapy by
either clinicians or the speech and language therapists
(table 1) and thereafter in follow up at 6 monthly
intervals.
The insertion of prophylactic feeding tubes (RIGs and
PEGs) were the preferred option in view of the pre-
dicted intensity of treatment.
T r i s m u s ,d e f i n e dl e s st h a n3 5m mm o u t ho p e n i n ga t
incisors, was also assessed pre- and post- treatment.
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immediately post treatment and subsequently during
routine follow up clinics.
The department protocol for follow-up by clinicians
was weekly during treatment and once radiotherapy was
complete until the acute reactions had subsided suffi-
ciently. Patients were then reviewed initially after 3
weeks, then 6 weekly for the first 12-18 months and at
less frequent intervals thereafter. Patients if free of dis-
ease and significant toxicity were offered discharge at 5
years.
Results
24 patients were identified who received parotid-sparing
IMRT between 1/2003 and 11/2007 and who had stage
III/IV tumours (table 2). No other patients were identi-
fied who had not been treated by a full inverse-planned
approach during this period.
63% were T1/2, 33% T3/4 and 4% unclassified. 29%
were N0, 8% N1, 59% N2 and 4% N3. 10/24 had pri-
mary RT, 14/24 had primary surgery.
Of those receiving primary RT, all bar one received a
dose of 65Gy in 30# over 6 weeks (the other missed one
fraction due to hospital admission). For those receiving
post operative radiotherapy (n = 14), 9 (64%) received
65Gy/30#, 4 (29%) had 54Gy/36# and 1 (7%) received
64Gy/30# (table 3).
In total 50% of patients received concurrent che-
motherapy. In the majority of patients this was in the
form of weekly cisplatin at a dose of 35 mg/m
2 and for
an average of 5 cycles.
Target Volumes
The mean combined planning target volume treated was
918 cm
3 (range 293.9 cm
3 - 2104.8 cm
3). Averages for
individual PTVs were PTV1 391.7 cm
3, PTV2 311.7 cm
3
and PTV3 191.0 cm
3. The figures take account that in
some cases only two dose levels (and hence volumes
were utilised). 8.3% (n = 2) patients received unilateral
neck irradiation, the rest bilateral.
Acute Toxicity
54% developed Grade 3 mucositis. No patients devel-
oped Grade 4 mucosal reactions. 12% required delay of
radiotherapy or discontinuation but by no more than
one fraction. 42% did not complete all 6 planned cycles
of concurrent chemotherapy. One patient switched to
carboplatin after 3 cycles of cisplatin as this was poorly
tolerated but only received one further cycle.
25% (n = 6) of patients were admitted during treat-
ment- one for an aspiration pneumonia, three for vomit-
ing following concurrent chemo-radiation, one with
constipation following chemo-radiation and one with
diarrhoea and vomiting during radiotherapy alone.
The mean weight loss during radiotherapy was 9.26 kg
(median 9 kg) which accounted for a mean of 12.75% of
body weight (assessable in 19 patients). All but one
patient had a gastrostomy (RIG) tube inserted
prophylactically.
Late Toxicity
At mean follow-up of 20.7 months, 18% had returned to
a normal diet (TOM score 5), 41% required some diet-
ary modifications (TOM score 4), 18% required oral
feeding supplements (TOM 3) and 23% were still depen-
dent on nutritional support by means of RIGs (TOM
scores of 0, 1 and 2). With longer follow-up (mean 37.1
months), TOM scores were 62.5%, 12.5%, 8% and 17%
respectively. Of surviving patients at a mean follow up
of 3.1 months post treatment, 2 still had RIG tubes in
Table 1 TOM Score (Disability Domain)
0 Non oral feeding/supplements required to meet all hydration/
nutritional needs
1 Non oral feeding/supplements required to meet hydration/nutritional
needs. Consistently able to take practice amounts
2 Non oral feeding/supplements required to meet hydration/nutritional
needs. Consistently able to take practice amounts
3 Consistently able to take modified consistencies using compensatory
strategies. May require feeding supplements. May eat extremely
slowly
4 Although eating & drinking is abnormal, it is good enough to meet
nutritional requirements. No supplements. May avoid certain foods
or eating situations
5 Functionally eating & drinking a normal diet
Table 2 Table of Patient Characteristics
Age Median 53.5
Range 44-74
Sex Male 18
Female 6
Primary site Tonsil 11
Base of tongue 10
Soft palate 2
Posterior pharyngeal wall 1
Table 3 Table of Treatment Received
Primary radiotherapy (n = 10) Neoadjuvant Cisplatin/5FU 1
Carboplatin/5FU 1
Concurrent Cisplatin 4
Carboplatin 1
Cetuximab 1
Post-operative radiotherapy (n = 14) Concurrent Cisplatin 4
Carboplatin 1
Cetuximab 1
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recover post RT, it took on average 8.7 months to
return to near normal eating function (i.e. TOM score
of 4 or 5) (figures 1&2).
Of those patients who did not recover their baseline
swallowing function, 56% (n = 5) were post operative. Of
the patients who died within the follow up time, none
regained their baseline swallowing function (n = 4).
There is long term data available for 83% of patients
with regards to rates of trismus. 15% (n = 3) of these
experienced trismus secondary to the radiotherapy itself.
10% (n = 2) had trismus which predated the radiother-
apy. Trismus was actively managed with the use of regu-
lar spatula placement and/or the use of commercial
devices (Therabite®).
One patient has developed a pharyngeal stricture and
one patient only symptomatic osteoradionecrosis though
residual disease was noted in the resected and recon-
structed tissue. With a median follow-up of 31.6
months, 16.5% patients have died (n = 2 recurrence, n =
2 intercurrent illness).
Survival
The 2 year overall survival was 92% (n = 22), and dis-
ease specific survival 96% (n = 23) (figure 3).
Discussion
The management of oropharyngeal cancer has under-
gone several treatment intensification strategies in order
to improve disease control. In the main this has been
through the use of concurrent chemotherapy but also
targeting patients who historically might have been con-
sidered untreatable. At the same time, intensity-modu-
lated radiotherapy (IMRT) has facilitated accurate dose
delivery to carefully defined and delineated volumes.
Uncertainty exists on the impact of intermediate doses
delivered to normal tissues particularly concurrently
with chemotherapy [16]. In addition, emerging data sug-
gests an improved outcome for patients who are HPV
positive and speculation that these patients might be
suitable for treatment ‘de-intensification’ [17].
Our series has demonstrated excellent disease control
for patients who historically have fared poorly. Menden-
hall et al. in 2006 reported on one series of over 300
patients with base of tongue primaries [18]. In this ser-
ies, local control rates at 5 years for Stage III, 82%; IVA,
87%; and IVB, 58%; the rates of absolute and cause-spe-
cific survival at 5 years were as follows: III, 66% and
77%; IVA, 67% and 84%; and IVB, 33% and 45%.
Assessments using subjective measures such as qual-
ity of life questionnaires, such as the University of
Washington Quality of Life Scale [19] and objective
assessments, for example, video fluoroscopy can be
used to evaluate functional outcomes. The former
could vary day to day dependent on patients’ mood,
and the latter is time consuming, invasive and expen-
sive. The advantage of the TOM score as used here is
that it can be performed swiftly at each and every
review at the time or later potentially later, depending
on the quality of the notes recorded. In considering
the overall TOM score, we looked at both the ability
to maintain nutrition orally and the amount of effort
and compensatory techniques employed to achieve
this.
It is standard practice within our department for
patients receiving oropharyngeal and neck radiotherapy
to have percutaneous enteral nutrition. Enteral nutrition
has been shown to prevent weight loss, dehydration,
nutritional deficiencies, treatment interruptions and hos-
pitalisations along with providing an improved quality of
life [20].
In one study of patients with pharyngeal squamous
cell carcinoma who received radical radiotherapy in
1998-2002, 83% had some degree of dysphagia [21].
Aspiration was recorded in 18%. Fibreoptic evaluation of
swallowing and quality of life questionnaires were used
to assess patients after treatment. In comparison, 4%
(n = 1) in our series developed any complications from
aspiration. There may be an element of silent aspiration
in this cohort but we also took a proactive approach to
swallowing dysfunction during and post-treatment. FEES
was used to evaluate any patients we had any concerns
about in order to inform our advise and to facilitate and
practice compensatory and rehabilitative techniques at
appropriate times.
Rosenthal noted that 20% of patients post radiother-
apy required long term enteral feeding [22] compared
with our figure of 8%. Mekhail et al. found the average
time for a PEG feeding tube to be in situ was 6.5
Figure 1 Graph illustrating the recovery of TOM score over
time for patients who recovered to at least their baseline
swallowing function (n = 15) (Shaded area represents time
during radiotherapy).
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an average of 3.1 months post completion of
radiotherapy.
Rademaker et al, 2003 indicated that it took approxi-
mately 1 year to recover eating ability to near normal
level [24]. In our series recovery was somewhat shorter
at an average of 8.7 months. We routinely see our
patients before, during and after treatment in order to
assist with swallow rehabilitation and encourage them
back towards attempting oral foods. A monthly joint
nutrition/SLT clinic is held where appropriate advice
and decisions about adequacy of enteral feeds can be
actioned as oral intake increases.
When treating oropharyngeal cancers, radiotherapy
using a large radiation portal field (>11 cm) has been
s h o w nt oh a v eas i g n i f i c a n ti m p a c t( p<0 . 0 0 1 )o n
swallowing dysfunction [25]. The work spans a pre-
and post-IMRT era. Previous studies have confirmed
the significant decrease in volume of tissue irradiated
when using IMRT techniques compared with standard
non-conformal plans. Some studies have shown that
irradiation of the pharyngeal constrictor muscles play a
role in resulting dysphagia. One study of 88 patients
with oropharyngeal carcinomata treated with radio-
therapy with or without concurrent chemotherapy sug-
gested a probability of dysphagia of 19% with every
additional 10Gy to the constrictor muscles [26]. How-
ever, a further smaller study by Bhide et al. [27] did
not find a statistically significant relationship between
radiation dose to the pharyngeal constrictors and dys-
phagia at 1 year post chemo-radiation for head and
neck cancer. Further investigation in this area is war-
ranted. In our series, no specific attempt was made to
spare the pharyngeal constrictors. In part this was
b e c a u s et h e yw e r en o tw e l lv i s u a l i s e d( p l a n n i n gM R I s
have since been adopted), there is no consensus yet on
their anatomical definition and due to a policy that
still exists of ‘anatomical’ rather than ‘volumetric’ pri-
mary target inclusion.
Trismus
Trismus is has been noted to be exceedingly common
both post conventional radiotherapy and IMRT to head
and neck cancer, with one study suggesting a rate of
45% [28]. The rate of trismus in this series is low at 15%
and may reflect the pro-active approach in its preven-
tion. Previous studies have shown an increase in man-
dibular dysfunction as radiation dose to the pterygoids
is increased [29]. With the increased conformality that
IMRT is able to offer, similar to the potential benefit of
dose constraint to the constrictor muscles, there may
also be some benefit to sparing of the contralateral
pterygoid muscles. Although in this series there was no
s p e c i f i cd o s ec o n s t r a i n to nt h e s em u s c l e sa n da‘whole-
organ’approach was used (i.e. the whole oropharynx),
the contralateral pterygoid muscles were generally
excluded from the primary CTV.
Weight Loss
Median weight loss during treatment previously has
been recorded as 18 lbs (8.16 kg) by Nguyen et al. [30].
This is comparable with our median weight loss of 9.26
kg (20 lbs) despite proactive management. In the
Nguyen series, weight loss of more than 20% during
treatment predicted for poor outcome with regards to
not regaining baseline swallowing function (p = 0.0002).
This highlights the importance of multidisciplinary team
assessments during radiotherapy and the necessity for
feeding supplements throughout. In addition, weight
loss can mean a change in body contour in the treated
Figure 2 Graph illustrating the recovery of TOM score over
time for patients who did not recover their baseline
swallowing function (n = 9).
Figure 3 Kaplan Maier curve showing overall survival
probability (%) against time (months).
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volumes. We found no evidence of this being an issue
in our series. We are currently evaluating the role of
weekly cone-beam KV CT imaging to assess for set-up
errors (in addition to daily KV-KV planar imaging) and
the potential for adaptive planning based on tumour
response and/or changes in body profile. The potential
value has been demonstrated elsewhere [31].
Admission Rates
Admission rates, although high, are in keeping with
other published series. Brady et al. [32] looked at admis-
sion rates for patients undergoing radiotherapy with or
without concurrent chemotherapy for head and neck
primaries and reported this to be 28% during treatment.
Conclusions
Excellent disease control with intensified schedules of
radiotherapy with IMRT has been achieved in this
patient population with locally advanced oropharyngeal
SCC. Intermediate toxicity is significant but with longer
follow-up, dysphagia continues to improve with 75% of
patients not requiring any form of enteral or oral
supplementation.
Social and emotional aspects of eating and drinking
difficulties are important factors to consider alongside
the initial physical recovery of swallow function and the
ability to maintain nutrition orally. Ongoing informed
support and appropriate and timely encouragement
from clinical staff, carers and volunteers in addressing
these issues contributes greatly towards long-term self
management and survivorship. The TOM scoring sys-
tem, as used here, provided a useful means of evaluating
functional recovery of swallowing.
The data lends support to such intensive treatment
approaches to achieve maximal cure rates but is reliant
on good multi-disciplinary working and appropriate
patient selection.
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